BioPharma Resources

Drug Trial Radar · NCT07910903

Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma

A Randomized, Open-Label, Multicenter, Phase 3 Study To Compare the Efficacy and Safety of CM336 + CM313 Combination Therapy Versus Daratumumab + Pomalidomide +Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

May 2030

Study completion Nov 2030

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of two parts. The purpose of Part 1 is to evaluate the safety and tolerability of CM336+CM313 combination therapy in participants with relapsed or refractory multiple myeloma (RRMM). Part 2 is to compare the efficacy of CM336 + CM313 (Group A) with Daratumumab + Pomalidomide +Dexamethasone (DPd) (Group B) in RRMM patients.

Conditions

  • Multiple Myeloma (MM)

Interventions

  • CM336Drug

    Specified dose on specified days

  • CM313Drug

    Specified dose on specified days

  • DaratumumabDrug

    Specified dose on specified days

  • PomalidomideDrug

    Specified dose on specified days

  • DexamethasoneDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Frequency of Adverse Events (AEs)Time frame: Up to 4 years
  2. Part 2: 9-Month Minimal Residual Disease (MRD) Negative Complete Response (CR)Time frame: At month 9
  3. Part 2: Progression Free Survival (PFS)Time frame: Up to 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.